News

Stimulating Interactions

NEWS

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth QB3@953, a biotech incubator, has been so successful that many of the startups housed there are searching for larger laboratories in Southside San Francisco. But their moves have been stymied by high rents and real estate prices, as well as a lack of space for midsize companies. The incubator, launched almost […]

Read more

Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors

Pfizer ($PFE) announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease […]

Read more

Amarantus Inks Deal to Merge Dx Unit with Avant Diagnostics

NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings announced today that it has signed a letter of intent to merge its Amarantus Diagnostics subsidiary with Avant Diagnostics. Upon the close of the merger, Avant will issue Amarantus Bio 80 million shares of its common stock, representing roughly 45 percent of the combined company’s outstanding shares. Avant will also issue Amarantus Bio […]

Read more

Dementia Discovery Fund Chooses Alector for First Investment

LONDON—A promising new avenue in Alzheimer’s research that focuses on the eradication of brain plaque by the immune system has become the first investment for a $100 million fund dedicated to delivering new dementia drugs within a decade. The Dementia Discovery Fund, set up last year with backing from the U.K. government and several of the world’s biggest pharmaceutical companies, […]

Read more

Alector Announces $29.5M Series D Financing

Alector Announces $29.5M Series D Financing Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, today announced that it has raised $29.5 million in a Series D financing. After having completed a Series C financing of $32 million earlier in the year, this financing brings the total amount […]

Read more

4D Molecular Therapeutics Announces Collaboration With Pfizer, Inc.

4D Molecular Therapeutics Announces Collaboration With Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and a collaboration and license agreement with Pfizer Inc. to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease […]

Read more

Fay Christodoulou, CSO, Miroculus

The notion of small molecules that detect dozens of cancers may sound like something out of a science-fiction novel. But for Christodoulou and her peers at Miroculus, it’s more akin to a modern-day reality. The company has trained its sights on microRNA, which Christodoulou describes as small molecules that reflect a person’s health state and which might be used as […]

Read more

David Whitlock of AOBiome | Q&A

Chemical engineer David Whitlock has made a splash in the media as of late, due to his lack of “splash”—as in the man hasn’t bathed in 12 years. The reason behind such a choice? David is working to defend the bacteria that live on his skin—as it does on ours—but Whitlock also believes it’s in our best interest to keep […]

Read more

How Bell Biosystems is using naturally magnetic bacteria to track cell therapies

With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles’ longevity and strong signals lend the agents advantages for large animal and human studies, the company is hoping to make its mark in the preclinical space before tackling what will likely […]

Read more

Amarantus Announces Issuance of Australian Patent

Amarantus Announces Issuance of Australian Patent Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, today announced the issuance of Australian patent no. 61/057,713 covering the use of Eltoprazine for the treatment of various neurological and mental disorders, including Parkinson’s disease, […]

Read more
Page 4 of 8« First...23456...Last »

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    14:00-15:30
    08/31/2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter